Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026 at 1:00 p.m. Eastern Time at the InterContinental Boston Hotel, with the overall event taking place in person from August 11–13, 2026.
A live webcast and presentation slides will be accessible via the provided link, with a replay available for 365 days. Entera is a clinical-stage company developing oral peptide and protein replacement therapies, including lead osteoporosis candidate EB613, which met primary and secondary endpoints in a Phase 2 study.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 27 | Private placement | Negative | +91.2% | Private placement raised $275 million but involved substantial share issuance |
| Jun 22 | FDA feedback | Positive | +22.3% | FDA accepted a single 750-patient Phase 3 trial supporting potential NDA submission |
| Jun 16 | Preclinical data | Positive | -2.5% | EB612 and EB618 showed pharmacologic effects and supported advancement toward clinical development |
| Jun 15 | Clinical data | Positive | -1.6% | Single-tablet EB613 showed comparable PK/PD, calcemic effects and safety to comparators |
| May 28 | Presentation acceptance | Positive | +2.5% | Multiple oral peptide pipeline abstracts were accepted for ENDO 2026 presentations |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or strategically important announcements produced mixed reactions, with three aligned moves and two divergences.
Key Terms
PTH(1-34) medical
osteoanabolic medical
placebo-controlled medical
dose-ranging medical
BMD medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, details as below.
Canaccord Genuity 46th Annual Growth Conference (Fireside Chat and 1x1 Meetings)
Date and Time: August 12, 2026 at 1:00 p.m. Eastern Time
Location: In person, August 11–13, 2026, InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, MA
Webcast: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/3r4fss8AzFCZNhJDzPz9Sa
A live webcast of the discussion, including presentation slides, will be available at the link above. A replay will remain accessible for 365 days following the event.
About Entera
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.
Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Company Contact:
IR@enterabio.com
